NL2026426A - Fluorine-containing graphene quantum dots, preparation method and application thereof as photosensitiser for photodanamic therapy - Google Patents
Fluorine-containing graphene quantum dots, preparation method and application thereof as photosensitiser for photodanamic therapy Download PDFInfo
- Publication number
- NL2026426A NL2026426A NL2026426A NL2026426A NL2026426A NL 2026426 A NL2026426 A NL 2026426A NL 2026426 A NL2026426 A NL 2026426A NL 2026426 A NL2026426 A NL 2026426A NL 2026426 A NL2026426 A NL 2026426A
- Authority
- NL
- Netherlands
- Prior art keywords
- fluorine
- quantum dots
- containing graphene
- graphene quantum
- oxidized
- Prior art date
Links
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 229910052731 fluorine Inorganic materials 0.000 title claims abstract description 98
- 239000011737 fluorine Substances 0.000 title claims abstract description 98
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 title description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 58
- 229910021389 graphene Inorganic materials 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 33
- 238000002428 photodynamic therapy Methods 0.000 claims abstract description 27
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 21
- 239000002096 quantum dot Substances 0.000 claims abstract description 14
- 238000006862 quantum yield reaction Methods 0.000 claims abstract description 14
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
- 239000001301 oxygen Substances 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 238000007248 oxidative elimination reaction Methods 0.000 claims abstract description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 25
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 10
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 10
- 239000012498 ultrapure water Substances 0.000 claims description 10
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- 239000007800 oxidant agent Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 206010040844 Skin exfoliation Diseases 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- 229910017604 nitric acid Inorganic materials 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract description 13
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract description 13
- 201000004101 esophageal cancer Diseases 0.000 abstract description 13
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 8
- 230000003013 cytotoxicity Effects 0.000 abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 4
- 208000000453 Skin Neoplasms Diseases 0.000 abstract description 4
- 201000005202 lung cancer Diseases 0.000 abstract description 4
- 208000020816 lung neoplasm Diseases 0.000 abstract description 4
- 201000000849 skin cancer Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 9
- 230000005284 excitation Effects 0.000 description 7
- 229930187593 rose bengal Natural products 0.000 description 7
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 7
- 229940081623 rose bengal Drugs 0.000 description 7
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- YAXWOADCWUUUNX-UHFFFAOYSA-N 1,2,2,3-tetramethylpiperidine Chemical compound CC1CCCN(C)C1(C)C YAXWOADCWUUUNX-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002120 nanofilm Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- BDXJANJAHYKTMI-UHFFFAOYSA-N 2,3,4,5-tetramethyl-1h-pyrrole Chemical class CC=1NC(C)=C(C)C=1C BDXJANJAHYKTMI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- DNUYOWCKBJFOGS-UHFFFAOYSA-N 2-[[10-(2,2-dicarboxyethyl)anthracen-9-yl]methyl]propanedioic acid Chemical compound C1=CC=C2C(CC(C(=O)O)C(O)=O)=C(C=CC=C3)C3=C(CC(C(O)=O)C(O)=O)C2=C1 DNUYOWCKBJFOGS-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000004729 solvothermal method Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- -1 tetramethylazolium salt Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/65—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
- C01B32/182—Graphene
- C01B32/184—Preparation
- C01B32/19—Preparation by exfoliation
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
- C01B32/182—Graphene
- C01B32/198—Graphene oxide
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Composite Materials (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Fluorine-containing graphene quantum dots, a preparation method and use of them as a photodynamic therapy photosensitizer are disclosed. The new quantum dots are prepared by using a fluorinated graphite as a raw material and a Hummers method to obtain an oxidized fluorine-containing graphene. Next, a chemical oxidative cleavage reaction is performed to obtain the fluorine-containing graphene quantum dots. The new fluorinecontaining graphene quantum dots have an average thickness of 1.0-3.0 nm, a size of 2.0-3.0 nm, a fluorine content of l%-2%, an oxygen content of 20%-30%, and a carbon content of 60%- 70%. They are smaller and more uniform in size and morphology, stable in structure, high in singlet oxygen quantum yield under visible light irradiation, very low cytotoxicity, and good water solubility, which makes them an ideal photosensitizer for photodynamic therapy useful for the early treatment of esophageal cancer, skin cancer, lung cancer and other diseases.
Description
-1- FLUORINE-CONTAINING GRAPHENE QUANTUM DOTS, PREPARATION
TECHNICAL FIELD The present invention belongs to the technical field of nano-medical materials, and more particularly, to fluorine-containing graphene quantum dots, a preparation method and an application thereof as a photodynamic therapy photosensitizer.
BACKGROUND Graphene quantum dots (GQDs) represent a new type of carbon quantum dots with unique properties. It is a zero-dimensional material with characteristics derived from both graphene and carbon dots, which is essentially a small piece of graphene smaller than 10 nanometers. GQDs are slated to substitute traditional semiconductor quantum dots and organic dyes in life sciences applications. Because of their excellent biocompatibility, superior resistance against photobleaching, good fluorescence performance, and easy surface modification, graphene quantum dots have gained tremendous attention for their potential in biomarking, bioimaging, and photodynamic therapy applications.
Photosensitizers (PSs) play a vital role in photodynamic therapy (PDT), a triggering strategy typically used in the treatment of superficial tumors. During PDT, the photosensitizer absorbs the photon energy having a suitable wavelength and transitions to an excited state. Reactive oxygen species (ROS), such as singlet oxygen, are produced by energy transfer from an excited photosensitizer, and eventually, cancer cells are killed by the produced cytotoxic ROS. PDT has been used to treat a variety of cancers such as esophageal cancer, skin cancer, and early stage lung cancer. Compared with traditional tumor therapies, the advantage of PDT is the ability to treat tumors accurately and effectively, with fewer side effects.
Current reported works involving GQDs utilized as PDT photosensitizers indicate a fluorescence emission peak at 700 nm and a singlet oxygen (102) quantum yield of 1.3 (relative yield). However, the as-reported synthesis process is complicated. They are
-2- prepared by changing the terminal group structure of the thiophene monomer, which has poorer hydrophilicity and greater cytotoxicity. There is current work involving fluorinated graphene quantum dots. These are fluorine- containing graphene quantum dots with sizes of 2.5 nm to 3.5 nm synthesized by a solvothermal method using fluorinated graphite as a raw material, but their fluorine content is as high as 17%-25%. In the synthesis process, the procedures are complicated and cumbersome, which is not conducive to practical applications. Unfortunately, the aforementioned fluorinated graphene quantum dots have not been used in the study of PDT photosensitizers. Another source reporting synthesis of fluorinated graphene quantum dots indicates production by a microwave-assisted hydrothermal method using fluorinated graphite as a raw material. Although the fluorinated graphene quantum dots have a fluorine content aslow as 1.2%, their size is slightly larger (3.0 nm to 10.0 nm), and the synthesis process is relatively complex. In addition, these fluorinated graphene quantum dots have not been used in the study of PDT photosensitizers. Chinese patent (CN201610935474.4) discloses a method of synthesizing fluorinated graphene quantum dots, but due to the different raw materials and synthesis of the patented methods, the subject fluorinated GQDs are not uniform in size, and the fluorine content is inconsistent and unclear. Moreover, they also have not been used in the study of PDT photosensitizers.
SUMMARY In view of the above-mentioned problems in the prior art, the present invention provides fluorine-containing graphene quantum dots that are small in size, have good water solubility, high singlet oxygen generation efficiency and a stable structure, which can be optimally used in PDT.
The fluorine-containing graphene quantum dots of the present invention are prepared by using a fluorinated graphite as a raw material and a Hummers method to obtain an oxidized fluorine-containing graphene, and then performing a chemical oxidative
-3- cleavage reaction to obtain the fluorine-containing graphene quantum dots, with an average thickness of 1.0 nm to 3.0 nm, a size of 2.0 nm to 3.0 nm, a fluorine content of 1%-2%, an oxygen content of 20%-30%, a carbon content of 60%-70%, and a 'O: quantum yield of 0.4-0.5 under visible light irradiation.
A preparation method of the fluorine-containing graphene quantum dots of the present invention includes the following steps: 1) performing an ultrasonic peeling treatment of the fluorinated graphite with a strong alkaline substance and then using a Hummers method to prepare the oxidized fluorinated graphene; 2) weighing and dissolving the oxidized fluorine-containing graphene in ultrapure water, performing an ultrasonic treatment to disperse sufficiently to obtain a solution; adding a strong oxidizer to the solution, followed by adding lye, refluxing for 5-9 hours at 60-100°C, to fully carry out the chemical oxidative cleavage reaction; and 3) after the refluxing is completed, filtration, purification, and drying to obtain the fluorine-containing graphene quantum dots. In the preparation method of the fluorine-containing graphene quantum dots described above, the strong alkaline substance in step 1) can be sodium hydroxide, potassium hydroxide, and the like, which can be prepared into an alkaline solution for better soaking graphite. There is no special requirement for a concentration of the alkali solution, a mass concentration of the alkali solution can generally be between 10%-80%, and more preferably between 20%-50%, soaking and peeling at high concentration takes a short time, and soaking and peeling at low concentration takes slightly longer.
The oxidized fluorinated graphene obtained in step 1) has a fluorine content of 6%-8%, an oxygen content of 6%-8%, and a carbon content of 80%-90%. In this step, the fluorinated graphite can be soaked in a strong alkaline solution to achieve peeling. The step of using the Hummers method to prepare the oxidized fluorinated graphene is disclosed in the following publication: ACS Nano, 2010, 4 (8), 4806-4814, the contents of which is incorporated herein by reference. In the preparation method of the fluorine-containing graphene quantum dots described
-4- above, the strong oxidizer in step 2) may be a mixture of one or more of hydrogen peroxide, concentrated sulfuric acid, concentrated nitric acid, and potassium persulfate.
In the preparation method of the fluorine-containing graphene quantum dots described above, a mass ratio of the oxidized fluorine-containing graphene and the strong oxidizer in step 2) may be (1-3):(1000-3000), preferably (1-3):1000; and a mass ratio of the oxidized fluorine-containing graphene to the ultrapure water may be (1-3):(1000-3000), preferably 1:(1000-3000).
As an improvement, for the preparation method of the fluorine-containing graphene quantum dots described above, an ultrasonic power in step 2) may be 500-800 watts; the strong oxidizer may be a mixture of one or more of hydrogen peroxide, concentrated sulfuric acid, and concentrated nitric acid; and the lye can be potassium hydroxide solution, sodium hydroxide solution, ammonia water, and the like, which mainly promotes the chemical oxidative cleavage reaction and has a catalytic effect, and its concentration can generally be 0.5-2 mol/L.
As an improvement, for the preparation method of the fluorine-containing graphene quantum dots described above, the purification in step 3) may be performed by suction filtration, chromatography, dialysis, filtration, extraction, distillation and fractionation, and the like; and the drying can be vacuum drying, freeze drying, high temperature drying, and the like.
The fluorine-containing graphene quantum dots of the present invention can be used as a photosensitizer for photodynamic therapy.
The surface of the fluorine-containing graphene quantum dots of the present invention is rich in hydroxyl and carboxyl groups, and the interior is mainly composed of sp? hybridized carbon atoms, which has a good water-solubility (see FIG. 1 and FIG. 3). In the ultraviolet-visible light region, the fluorine-containing graphene quantum dots have superior absorption (see FIG. 2) and excitation-independent luminescence properties; and under visible light irradiation, the !O2 quantum yield can reach 0.4-0.5. The fluorine- containing graphene quantum dots of the present invention have stable structure, high
-5- efficiency in producing singlet oxygen, low cytotoxicity, good water solubility and excellent biocompatibility. They are ideal photosensitizers for PDT, and can be better applied in PDT. However, the prior art GQDs have poor cytotoxicity and lack biocompatibility. Additionally, prior GQDs are difficult to be used as a PDT photosensitizer. Compared with the prior art, the present invention has the following advantages.
1) The fluorine-containing graphene quantum dots prepared by the present invention are biomedical nanomaterials with hydrophilic groups such as hydroxyl, carboxyl, and amino groups on the surface. The material is smaller and more uniform in size and morphology, has stable optical performance and easy surface modification, and can be well dispersed in water, phosphate buffer solution, biological culture medium and other aqueous solution systems.
2) The cytotoxicity of the fluorine-containing graphene quantum dots prepared by the present invention was tested by the MTT method (tetramethylazolium salt). The test results show that after co-cultivating esophageal cancer cells with different concentrations of fluorinated graphene quantum dots in 1640 medium solution for 12 hours, the survival rate of the esophageal cancer cells is still maintained at more than 90%, indicating that the fluorine-containing graphene quantum dots prepared by the present invention have very low toxicity (see FIG. 6).
3) The fluorine-containing graphene quantum dots prepared by the present invention have good absorption in the ultraviolet-visible light region. When the fluorine- containing graphene quantum dots prepared by the present invention are irradiated with visible light, singlet oxygen can be generated (see FIG. 5), and the O2 quantum yield is as high as 0.4-0.5. Compared with the ideal photosensitizer Rose Bengal (RB) currently used for photodynamic therapy, the +02 quantum yield of Rose Bengal (RB) is 0.75. In addition, compared with the reported use of existing graphene quantum dots as a photosensitizer for PDT, the 102 quantum yield of the fluorine-containing graphene quantum dots of the present invention reaches 0.4-0.5. Based on this, the fluorine- containing graphene quantum dots of the present invention can effectively kill tumor cells under visible light irradiation, and can be used as photosensitizers for PDT (see FIG. 7).
4) When the fluorine-containing graphene quantum dots prepared by the present
-6- invention are used in photodynamic therapy, they can also be used for biological imaging, and the operation process is simple, which is conducive to practical applications.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. Lis a transmission electron microscope spectrum of fluorine-containing graphene quantum dots of the present invention. FIG. 2 is a diagram showing an ultraviolet-visible absorption spectrum and a fluorescence emission spectrum of the fluorine-containing graphene quantum dots in ultrapure water (with an excitation wavelength of 320 nm). FIG. 3 is an X-ray photoelectron spectrogram of the fluorine-containing graphene quantum dots of the present invention. FIG. 4 is a scanning electron microscope spectrum of an oxidized fluorine-containing graphene of the present invention. FIG. 5 is an electron paramagnetic resonance spectroscopy (EPR) spectrum of 2,2,6,6- tetramethylpiperidine (TEMP) as a capturing agent of the fluorine-containing graphene quantum dots under the conditions of LED laser irradiation and without LED laser irradiation, respectively. FIG. 6 shows the results of the cytotoxicity test by MTT method after co-cultivation of the fluorine-containing graphene quantum dots of the present invention at different concentrations with esophageal cancer cells for 12 hours. FIG. 7 shows the results of the cytotoxicity test by MTT method after co-cultivation of the fluorine-containing graphene quantum dots of the present invention at different concentrations with esophageal cancer cells for 12 hours and then illumination for 12 minutes.
DETAILED DESCRIPTION OF THE EMBODIMENTS The following embodiments are further descriptions of the content of the present invention as an explanation of the technical content of the present invention, but the essential content of the present invention is not limited to the following embodiments. Those skilled in the art can and should know that any simple changes or substitutions
-7- based on the essential spirit of the present invention shall fall within the protective scope required by the present invention.
Embodiment 1 A method for preparing fluorine-containing graphene quantum dots that can be used for photodynamic therapy, specifically includes the following steps.
1) A fluorinated graphite is soaked in 30% sodium hydroxide solution, followed by stirring and dispersing ultrasonically for 12 hours to fully peel off, filtering, and drying. 2) The fluorinated graphite treated in step (1) is prepared into an oxidized fluorine- containing graphene by Hummers method; the oxidized fluorine-containing graphene has a fluorine content of 6%-8%, an oxygen content of 6%-8%, and a carbon content of 80%-90%, and it can be regarded as a two-dimensional nano film (see FIG. 4).
3) 60 mg of the above-mentioned oxidized fluorine-containing graphene is weighed and dissolved in 60 mL of ultrapure water, and treated with an ultrasonic power of 500 watts, and then 60 mL of hydrogen peroxide is added to fully dissolve the oxidized fluorine- containing graphene.
4) 400 pL of potassium hydroxide solution with a concentration of 1 mol/L is added to the above solution, and then the above solution is transferred to a round-bottom flask and refluxed in an oil bath at 60°C for 6 hours.
5) After the reflux, the above solution is purified by vacuum filtration with an organic microporous filter membrane with a pore diameter of 0.22 um to remove bulk impurities, and then dried to obtain fluorine-containing graphene quantum dots, which are characterized by smaller size (approximately 2.0-3.0 nm in lateral size), uniform morphology, excitation-independent luminescence, and, as set out below, other desirable biochemical properties.
6) The solution after the above reaction 1s put into a dialysis bag with a molecular weight cut-off (MWCO) of 500-1000 for dialysis, followed by rotary steaming, and freeze- drying to prepare fluorine-containing graphene quantum dots with an average thickness of 1.0-3.0 nm, a size of 2.0-3.0 nm, and a fluorine content of 1 %-2%.
FIG. 1 is a transmission electron microscope spectrum of the fluorine-containing graphene quantum dots. It can be seen that the fluorine-containing graphene quantum dots have good mono-dispersity and are flat round particles with a size of about 2 nm. FIG. 2 is a diagram showing an ultraviolet-visible absorption spectrum and a
-8- fluorescence emission spectrum of the fluorine-containing graphene quantum dots prepared by the present invention in ultrapure water (with an excitation wavelength of 320 nm). According to the analysis, the aqueous solution of fluorine-containing graphene quantum dots shows bright green fluorescence under the ultraviolet lamp of 365 nm, and has a fluorescence emission peak at 510 nm under 320 nm light excitation. FIG. 6 shows the cytotoxicity of the prepared fluorine-containing graphene quantum dots under dark conditions detected by the MTT method. After co-cultivation of esophageal cancer cells (provided by Anhui Medical University) with the fluorine- containing graphene quantum dots for 12 hours, the survival rate of the esophageal cancer cells remained above 90%, indicating that the prepared fluorine-containing graphene quantum dots have very low toxicity. Finally, the singlet oxygen generated by the prepared fluorine-containing graphene quantum dots in the aqueous solution is detected, and the steps are as follows.
(a) The synthesized fluorine-containing graphene quantum dots are weighed and mixed with ultrapure water to form a fluorine-containing graphene quantum dot solution with a concentration of 0.2 mg/mL.
(b) 1 mL of the 0.2 mg/mL fluorine-containing graphene quantum dot solution prepared above is added into a 2 mL centrifuge tube A, then 10 uL 2,2,6,6- tetramethylpiperidine (TEMP) is added to the centrifuge tube A, and then the centrifuge tube A is illuminated with LED light (with an excitation wavelength of 400-700 nm) for 12 minutes.
(c) 30-50 pL of the sample to be measured are extracted with a capillary tube with a diameter of 0.55 mm. Subsequently, the capillary tube is placed at a bottom of a test tube, the sample is adjusted to a center of the test tube, and then the test tube is placed in the electron paramagnetic resonance spectrometer (EPR), and the EPR tube is placed in a center position of the resonator cavity. EPR measurement parameters are as follows: central magnetic field, 3430.00 Gauss; sweep field width, 60.00 Gauss; scan times, 10; and time constant, 10.49 milliseconds.
(d) In addition, 1 mL of the 0.2 mg/mL fluorine-containing graphene quantum dot solution prepared above is added into a 2 mL centrifuge tube B, then 10 pL 2,2,6,6- tetramethylpiperidine (TEMP) is added to the centrifuge tube B, and then the centrifuge
-9- tube B is placed under a dark condition, and the operation step (c) was repeated. The results are shown in FIG. 3. It can be seen from FIG. 3 that the fluorine-containing graphene quantum dots have singlet oxygen generation signal under LED irradiation (with an excitation wavelength 400-700 nm), while in dark conditions there is only a small amount or even no singlet oxygen generation; and the 102 quantum yield of the fluorine-containing graphene quantum dots is 0.4-0.5.
The calculation method of 102 quantum yield is as follows.
The 10: quantum yield is evaluated by a chemical method. The water-soluble 9,10- anthracene diyl-bis(methylene) dimalonic acid (ABDA) is used as 10: capturing agent, and Rose Bengal (RB) is used as a standard photosensitizer. In short, 120 uL of ABDA solution (2.5 mg/mL) is added to 400 pL of fluorine-containing graphene quantum dot solution, and an LED lamp (400-700 nm) set at 40 milliwatts per square centimeter (mW/cm?) are used as the light source. In order to eliminate the inner-filter effect, the absorption maxima of Rose Bengal (RB) and the test sample are adjusted to be less than
0.2. The absorbance of ABDA is recorded at different irradiation times to obtain the decay rate of the photosensitization process. The 0: quantum yield of sample in water is calculated by the following formula: Dem=Pre* (Ksam*Ars) / (Kr* Asam) .
In the formula, Ksam and Krs are the decomposition rate constants of ABDA affected by the test sample and Rose Bengal (RB), respectively. Asam and Ars represent the light absorbed by the sample and Rose Bengal (RB), respectively, which are determined by integration of the optical absorption bands in the wavelength range of 400 to 700 nm. es is the 10: quantum yields of Rose Bengal (RB), ®rp=0.75 in water.
The fluorine-containing graphene quantum dots prepared by the present invention are used as photosensitizers in photodynamic therapy, which can generate a large amount of singlet oxygen under light, with a O2 quantum yield of 0.4-0.5, thereby improving the effect of photodynamic therapy. The fluorine-containing graphene quantum dots can be used in the treatment of various tumors, esophageal cancer, skin cancer, early lung cancer and other diseases.
-10- Culture conditions of esophageal cancer cells.
Esophageal cancer cells are placed in 1640 medium containing 8% fetal bovine serum, and then placed in an incubator at 37°C with 5% CO2. When the cells have proliferated to approximately fill the bottom of the culture flask, the old medium is removed, and 2 mL of phosphate buffer solution (PBS) that has been preheated to 37°C is added to wash the cells.
Subsequently, 1 mL of 0.25% trypsin solution is added to infiltrate cells, followed by centrifugation to remove the trypsin, digestion at 37°C for about 4 minutes, and then placed under an optical microscope to observe the morphological changes of the cells.
Finally, 2 mL of 1640 culture medium is added, the cells are detached by gently pipetting to form a single cell suspension, and 1640 culture medium is added to continue culturing the cells.
The cells are transferred to a 96-well plate at a required concentration to continue the culture.
The cytotoxicity of fluorine-containing graphene quantum dots is detected by the tetramethylazolium salt (MTT) method, which is a common method for the detection of cell survival and growth.
The detection principle is that succinate dehydrogenase in the mitochondria of living cells can reduce exogenous MTT to water-insoluble blue-purple crystalline formazan and then form deposits in the cells, while dead cells have no such function.
Subsequently, the crystalline formazan in the cells is dissolved by dimethyl sulfoxide, and the absorbance is measured using a microplate reader at a test wavelength of 563 nm with a reference wavelength of 630 nm.
The cell viability is standardized to that of cells cultivated in the culture medium.
The results of the MTT cytotoxicity assay showed that esophageal cancer cells were co- cultured with different concentrations of fluorine-containing graphene quantum dots for 12 hours, and then illuminated for 12 minutes, as can be seen from FIG. 6 and FIG. 7, after being illuminated by LED lights, the cytotoxicity of different concentrations of fluorine-containing graphene quantum dots is significantly greater than that in the dark, indicating that fluorine-containing graphene quantum dots can be effectively and safely applied in PDT.
Embodiment 2
-11- A method for preparing fluorine-containing graphene quantum dots, specifically includes the following steps.
1) A fluorinated graphite is soaked in 40% sodium hydroxide solution, followed by stirring and dispersing ultrasonically for 12 hours to fully peel off, filtering, and drying. 2) The fluorinated graphite treated in step (1) is prepared into an oxidized fluorine- containing graphene by Hummers method; the oxidized fluorine-containing graphene has a fluorine content of 6%-8%, an oxygen content of 6%-8%, and a carbon content of 80%-90%, and it regarded as a two-dimensional nano film.
3) 60 mg of the above-mentioned oxidized fluorine-containing graphene is weighed and dissolved in 60 mL of ultrapure water, and treated with an ultrasonic power of 800 watts, and then 20 g of concentrated sulfuric acid and concentrated nitric acid are added to fully dissolve the oxidized fluorine-containing graphene.
4) 600 pL of potassium hydroxide solution with a concentration of 1 mol/L is added to the above solution, and then the above solution is transferred to a round-bottom flask and refluxed in an oil bath at 70°C for 6 hours.
5) After the reflux, the above solution is subjected to extraction and purification treatment, and then freeze-drying treatment to obtain fluorine-containing graphene quantum dots with an average thickness of 1.0-3.0 nm, a size of 2.0 nm-3.0 nm, and a fluorine content of 1%-2%.
Embodiment 3 A method for preparing fluorine-containing graphene quantum dots, specifically includes the following steps.
1) A fluorinated graphite is soaked in 30% sodium hydroxide solution, followed by stirring and dispersing ultrasonically for 12 hours to fully peel off, filtering, and drying. 2) The fluorinated graphite treated in step (1) is prepared into an oxidized fluorine- containing graphene by Hummers method; the oxidized fluorine-containing graphene has a fluorine content of 6%-8%, an oxygen content of 6%-8%, and a carbon content of 80%-90%, and it regarded as a two-dimensional nano film.
3) 60 mg of the above-mentioned oxidized fluorine-containing graphene is weighed and dissolved in 60 mL of ultrapure water, and treated with an ultrasonic power of 600 watts, and then 60 mL of hydrogen peroxide is added to fully dissolve the oxidized fluorine- containing graphene.
-12- 4) 400 pL of potassium hydroxide solution with a concentration of 1 mol/L is added to the above solution, and then the above solution is transferred to a round-bottom flask and refluxed in an oil bath at 80°C for 5 hours.
5) After the reflux, the above solution is filtered and purified to remove bulk impurities, and then vacuum dried to obtain fluorine-containing graphene quantum dots with an average thickness of 1.0-3.0 nm, a size of 2.0 nm-3.0 nm, and a fluorine content of 1%- 2%.
The fluorine-containing graphene quantum dots prepared by the present invention have the advantages of simple reaction steps, low cost and environmental protection, are easily dispersed in aqueous systems such as water, phosphate buffer solution, and biological culture medium, and have good biocompatibility and low toxicity.
The fluorine-containing graphene quantum dots prepared by the present invention can generate singlet oxygen under the light irradiation of visible light, which can be used as photosensitizers in photodynamic therapy, applicable to the treatment process of esophageal cancer, skin cancer, early lung cancer, and other diseases, and has a wide application prospect.
The foregoing descriptions are merely preferred embodiments of the present invention, which are not used to limit the present invention. Any modifications, equivalent substitutions, improvements within the spirit and principle of the present invention should be included in the protective scope of the present invention.
Claims (6)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910854472.6A CN111518552B (en) | 2019-09-10 | 2019-09-10 | Preparation of fluorine-containing graphene quantum dots and application of fluorine-containing graphene quantum dots as photodynamic therapy photosensitizer |
Publications (2)
Publication Number | Publication Date |
---|---|
NL2026426A true NL2026426A (en) | 2021-05-12 |
NL2026426B1 NL2026426B1 (en) | 2021-09-23 |
Family
ID=71900521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL2026426A NL2026426B1 (en) | 2019-09-10 | 2020-09-08 | Fluorine-containing graphene quantum dots, preparation method and application thereof as photosensitiser for photodanamic therapy |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN111518552B (en) |
NL (1) | NL2026426B1 (en) |
WO (1) | WO2021046966A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114479843B (en) * | 2021-12-20 | 2023-06-30 | 华南农业大学 | Preparation method and application of novel fluorescent nano material with photodynamic therapy and sterilization functions |
CN115403831B (en) * | 2022-09-13 | 2023-10-24 | 中国科学院深圳先进技术研究院 | Modified fluorinated graphene quantum dot, photosensitive composite material and application thereof |
CN116041176B (en) * | 2023-02-21 | 2024-06-25 | 武汉科技大学 | Molecular-grade hydrophilic graphene quantum dot and preparation method and application thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8865932B2 (en) * | 2010-12-22 | 2014-10-21 | Ocean's King Lighting Science & Technology Co., Ltd. | Fluorinated graphene oxide and preparation method thereof |
CN102660270A (en) * | 2012-05-03 | 2012-09-12 | 吉林大学 | Method for preparing fluorescent graphene quantum dots by solvothermal method |
CN104944403B (en) * | 2014-03-24 | 2017-04-26 | 中国科学院兰州化学物理研究所 | Preparation method of water-soluble bi-colour fluorinated graphene quantum dot |
CN105460920B (en) * | 2014-09-05 | 2018-02-27 | 中国科学院兰州化学物理研究所 | The preparation method of the controllable fluorinated graphene quantum dot of water miscible Oil repellent |
CN105271200B (en) * | 2015-11-06 | 2017-11-28 | 昆明物理研究所 | Fluorin doped graphene quantum dot and preparation method thereof |
CN105567229B (en) * | 2016-01-29 | 2018-01-30 | 天津大学 | Method prepared by Fluorin doped fluorescent carbon quantum dot |
CN105565310A (en) * | 2016-03-02 | 2016-05-11 | 桂林理工大学 | Method for preparing fluorine doped graphene quantum dot with excellent optical properties |
CN106477565B (en) * | 2016-10-24 | 2019-05-14 | 国家纳米科学中心 | A kind of fluorinated graphene quantum dot, and its preparation method and application |
CN109486483B (en) * | 2017-09-11 | 2021-11-23 | 天津大学 | Fluorine-nitrogen double-element doped fluorescent carbon quantum dot and preparation method thereof |
CN108423655B (en) * | 2018-03-29 | 2020-02-21 | 中国科学院福建物质结构研究所 | Preparation method of fluorine oxidized graphene |
CN108545729A (en) * | 2018-04-24 | 2018-09-18 | 常州烯思新材料科技有限公司 | The preparation method of high-efficient graphite alkene quantum dot |
CN108706579B (en) * | 2018-07-23 | 2020-11-10 | 广西师范大学 | Method for preparing fluorine-doped graphene quantum dots |
-
2019
- 2019-09-10 CN CN201910854472.6A patent/CN111518552B/en active Active
- 2019-10-17 WO PCT/CN2019/111622 patent/WO2021046966A1/en active Application Filing
-
2020
- 2020-09-08 NL NL2026426A patent/NL2026426B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN111518552A (en) | 2020-08-11 |
WO2021046966A1 (en) | 2021-03-18 |
NL2026426B1 (en) | 2021-09-23 |
CN111518552B (en) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL2026426B1 (en) | Fluorine-containing graphene quantum dots, preparation method and application thereof as photosensitiser for photodanamic therapy | |
Zhao et al. | Preparation of N-doped yellow carbon dots and N, P co-doped red carbon dots for bioimaging and photodynamic therapy of tumors | |
CN109568578B (en) | Preparation method and application of natural biomass quantum dots and biomass quantum dot-copper nanocomposite | |
CN110339357B (en) | Copper ion doped carbon dot, preparation and application thereof as photodynamic therapy photosensitizer | |
CN109321240B (en) | Orange fluorescent carbon dot and preparation method thereof | |
Soldà et al. | C 60@ lysozyme: a new photosensitizing agent for photodynamic therapy | |
CN113773667B (en) | Organic small molecule near infrared two-region fluorescent dye and preparation method and application thereof | |
Jiang et al. | Indocyanine green derived carbon dots with significantly enhanced properties for efficient photothermal therapy | |
CN108516533A (en) | A kind of preparation method of hair peak green fluorescent carbon point | |
CN111603559B (en) | Copper iodophor compound @ photosensitizer composite nanoparticle and application thereof as X-ray photodynamic therapy medicine | |
WO2022095131A1 (en) | Preparation method and application for carbon nanoparticle | |
CN113648414B (en) | Metal ion coordinated carbon dot/titanium dioxide heterojunction and preparation method and application thereof | |
Belik et al. | Synthesis, photophysical properties, and photochemical activity of the water-soluble dyad based on fullerene С 60 and chlorin e 6 derivatives | |
CN106970059B (en) | Preparation and application of two-photon fluorescent probe | |
CN108774249B (en) | Oxazine compound and application thereof | |
CN108421040B (en) | Conjugated polymer nanometer photosensitive material with two-photon imaging and photodynamic curative effects, and preparation and application thereof | |
Kou et al. | Self-assembled photosensitive carbon nanocrystals with broad-spectrum antibacterial bioactivity | |
WO2022056956A1 (en) | Carbon nanoparticles with near-infrared light emission characteristics, preparation method therefor and use thereof | |
CN108421041B (en) | Photodynamic therapy compound and preparation method and application thereof | |
CN114681611B (en) | Poly 3-thiopheneacetic acid modified PCN-224 composite material and preparation method and application thereof | |
Zhang et al. | Dual ligand-assisted assembly of metal–organic frameworks on upconversion nanoparticles for NIR photodynamic therapy against hypoxic tumors | |
Dai et al. | Study on the photodynamic performance of non-stoichiometric nano-tungsten oxide probe. | |
CN114933904B (en) | Ultrathin shell chiral cadmium selenide/cadmium sulfide material for optical diagnosis and treatment and preparation method and application thereof | |
CN110607173A (en) | Riboflavin carbon dot photosensitizer and preparation method thereof | |
Sajjad et al. | The photodynamic anti-tumor effects of new PPa-CDs conjugate with pH sensitivity and improved biocompatibility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM | Lapsed because of non-payment of the annual fee |
Effective date: 20231001 |